Design Therapeutics (DSGN) Preferred Shares Issued (2020 - 2021)
Design Therapeutics recorded quarterly Preferred Shares Issued of $124.7 million in Q1 2021, up 402196.77% quarter-over-quarter from $31000.0 in Q2 2020, and up 179.0% year-over-year from $44.7 million in Q1 2020.
Design Therapeutics' Preferred Shares Issued history runs 2 years deep, the most recent figure standing at $124.7 million for Q1 2021.
- In Q1 2021, Preferred Shares Issued rose 179.0% year-over-year to $124.7 million; the TTM figure through Dec 2021 stood at $124.7 million (up 178.8% YoY), while the FY2021 annual figure was $124.7 million, up 178.8% from the prior year.
- Preferred Shares Issued came in at $124.7 million for Q1 2021 at Design Therapeutics, up from $31000.0 in the prior quarter.
- In the past five years, Preferred Shares Issued ranged from a high of $124.7 million in Q1 2021 to a low of $31000.0 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 124.71 Mn |
| Mar 31, 2021 | 124.71 Mn |
| Jun 30, 2020 | 31,000.00 |
| Jun 30, 2020 | 31,000.00 |
| Mar 31, 2020 | 44.70 Mn |
| Mar 31, 2020 | 44.70 Mn |